| Fuente | Nº Citas | Fecha Actualización |
|---|---|---|
| scopus | 3414 | 13-11-2024 |
| wos | 3150 | 13-11-2024 |
Año: 2014
Journal Impact Factor (JIF): 55.8730
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| MEDICINE, GENERAL & INTERNAL | SCIE | 1/154 | Q1 | T1 | D1 |
Año: 2017
Journal Citation Indicator (JCI): 23,770
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| MEDICINE, GENERAL & INTERNAL | 1/298 | Q1 | T1 | D1 | 99,83 |
Año:
2014
CiteScore:
57,300
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| General Medicine | 7/3264 | Q1 | T1 | D1 |
SJR año:
2014
Factor de Impacto:
16,259
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Medicine (miscellaneous) | 5/2859 | Q1 | T1 | D1 |
| Agencia | Código de Proyecto |
|---|---|
| Abbott | - |
| Actelion | - |
| Altitude Pharma | - |
| Amgen | - |
| Asahi Kasei Pharma | - |
| AstraZeneca | - |
| Bayer | - |
| Biogen Idec | - |
| Biogen-Stromedix | - |
| Boehringer Ingelheim | - |
| Bristol-Myers Squibb | - |
| Celgene | - |
| Centocor | - |
| Chugai | - |
| Eisai | - |
| Eli Lilly | - |
| Excel | - |
| FibroGen | - |
| Forest | - |
| France Foundation | - |
| Fukuda Denshi | - |
| Galecto | - |
| Genentech | - |
| Gilead | - |
| GlaxoSmithKline | - |
| Harefield NHS Foundation Trust | - |
| Ikaria | - |
| ImmuneWorks | - |
| Imperial College London | - |
| InterMune | - |
| Kyorin | - |
| Matrix | - |
| MedImmune | - |
| Meiji Seika Pharma | - |
| Mesoblast | - |
| Moerae | - |
| Moerae Matrix | - |
| National Institute for Health Research | NF-SI-0512-10157 |
| National Institute for Health Research (NIHR) Southampton Respiratory Biomedical Research Unit at the University Hospital Southampton NHS Foundation Trust | - |
| NIHR Respiratory Disease Bio-medical Research Unit at the Royal Brompton | - |
| Novartis | - |
| Olympus | - |
| Ono Pharmaceutical | - |
| Pfizer | - |
| Philips Respironics | - |
| Promedior | - |
| Roche | - |
| Roche-Genentech | - |
| Sanofi-Aventis | - |
| Sanofi-Genzyme | - |
| Shionogi | - |
| Taiho Pharmaceutical | - |
| Takeda | - |
| Teijin Pharma | - |
| Terumo | - |
| Veracyte | - |
| Vertex | - |
| # | Autor | Afiliación |
|---|---|---|
| 1 | University Hospital Southampton NHS Foundation Trust (United Kingdom) | |
| 2 | Du Bois, Roland M. | Imperial College London (United Kingdom) |
| 3 | Raghu, Ganesh | University of Washington, Seattle (United States) |
| 4 | Azuma, Arata | Nippon Medical School (Japan) |
| 5 | Brown, Kevin K. | National Jewish Health (United States) |
| 6 | Costabel, Ulrich | Universitäts Klinikum Essen und Medizinische Fakultät (Germany) |
| 7 | Cottin, Vincent | Université de Lyon (France) |
| 8 | Flaherty, Kevin R. | Michigan Medicine (United States) |
| 9 | Hansell, David M. | Royal Brompton and Harefield NHS Trust (United Kingdom) |
| 10 | Inoue, Yoshikazu | National Hospital Organization, Japan (Japan) |
| 11 | Kim, Dong Soon | Ulsan University (South Korea) |
| 12 | Kolb, Martin | McMaster University (Canada) |
| 13 | Nicholson, Andrew G. | Royal Brompton and Harefield NHS Trust (United Kingdom) |
| 14 | Noble, Paul W. | Cedars-Sinai Medical Center (United States) |
| 15 | Selman, Moisés | Instituto Nacional de Enfermedades Respiratorias (Mexico) |
| 16 | Taniguchi, Hiroyuki | Tosei General Hospital (Japan) |
| 17 | Brun, Michèle | Boehringer Ingelheim France S.A.S. (France) |
| 18 | Le Maulf, Florence | Boehringer Ingelheim France S.A.S. (France) |
| 19 | Girard, Mannaïg | Boehringer Ingelheim France S.A.S. (France) |
| 20 | Stowasser, Susanne | Boehringer Ingelheim Pharma GmbH & Co. KG (Germany) |
| 21 | Schlenker-Herceg, Rozsa | Boehringer Ingelheim Pharmaceuticals, Inc. (United States) |
| 22 | Disse, Bernd | Boehringer Ingelheim Pharma GmbH & Co. KG (Germany) |
| 23 | Collard, Harold R. | University of California, San Francisco (United States) |
| # | Autoría grupal | Afiliación |
| 1 | Alfageme Michavila, Inmaculada (INPULSIS Trial Investigators) | Sin datos () |
